Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fraser

Showing results (571-580 of 598) with videos related to

Pageof 60
Sort By:
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Annals of Surgical Oncology|July 24, 2025
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Annals of Surgical Oncology|July 23, 2025
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 TrialMandeep Kaur, Katrina Dimitroff, Judy C Boughey, et al.
JAMA Surgery|September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 TrialMarie Osdoit, Christina Yau, W Fraser Symmans, et al.
NPJ Breast Cancer|August 23, 2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
NPJ Breast Cancer|January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
Pageof 60

Showing results (571-580 of 598) with videos related to

Sort By:
Pageof 60
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.
Annals of Surgical Oncology|July 24, 2025
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Annals of Surgical Oncology|July 23, 2025
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 TrialMandeep Kaur, Katrina Dimitroff, Judy C Boughey, et al.
JAMA Surgery|September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 TrialMarie Osdoit, Christina Yau, W Fraser Symmans, et al.
NPJ Breast Cancer|August 23, 2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
NPJ Breast Cancer|January 25, 2019
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response EndpointJudy C Boughey, Michael D Alvarado, Rachael B Lancaster, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
Pageof 60